The Prelieve Trial - Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Heart Failure Patients (PRELIEVE)
Prospective, Non-randomized, Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Heart Failure Patients With Reduced Ejection Fraction or in Heart Failure Patients With Preserved Ejection Fraction
Sponsor: Occlutech International AB
A NA clinical study on Heart Failure and Heart Failure Low Output, this trial is completed. The trial is conducted by Occlutech International AB and has accumulated 12 data snapshots since 2017. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Sep 2022 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Sep 2021 — Sep 2022 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Recruiting NA
-
Jul 2020 — Jan 2021 [monthly]
Recruiting NA
-
Apr 2019 — Jul 2020 [monthly]
Recruiting NA
-
Jun 2018 — Apr 2019 [monthly]
Recruiting NA
-
Sep 2017 — Jun 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jun 2017 — Sep 2017 [monthly]
Not Yet Recruiting NA
-
Feb 2017 — Jun 2017 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Occlutech International AB
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalst, Belgium , Ankara, Turkey (Türkiye) , Berlin, Germany , Brussels, Belgium , Cologne, Germany , Frankfurt, Germany , Ghent, Belgium , Hamburg, Germany , Hanover, Germany , Homburg, Germany and 9 more locations